Andere talen Enanta Pharmaceuticals, Inc.

Aandelen

ENTA

US29251M1062

Farmaceutische producten

Geschatte realtime Cboe BZX Andere beurzen 19:17:16 13-11-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,76 ^USD	-1,42%		+9,44%	+105,57%

20/10	Enanta Pharmaceuticals presenteert nieuwe gegevens over Zelicapavir en EDP-323, veelbelovende RSV-remmers	CI
02/10	Enanta Pharmaceuticals kondigt afsluiting aan van vergrote openbare aandelenemissie	RE

Andere talen

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences	04/11
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025	20/10
Enanta Pharmaceuticals, Inc. Presents New Data for Zelicapavir, its N-Protein Inhibitor and EDP-323, L-Protein Inhibitor	20/10
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025	07/10
Enanta Pharmaceuticals announces closing of upsized public offering of common stock	02/10
Enanta Pharmaceuticals Closes Stock Offering	02/10
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	02/10
Traders Weigh US Government Shutdown, Fueling Premarket Losses for US Equity Futures	01/10
Top Premarket Decliners	01/10
USA-Les valeurs à suivre à Wall Street (actualisé)	01/10
Enanta Pharmaceuticals Prices $65 Million Common Stock Offering; Shares Fall Pre-Bell	01/10
Enanta Pharmaceuticals prices upsized offering of 6,500,000 shares at $10 each	01/10
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock	01/10
Enanta Pharmaceuticals Launches Public Offering of Common Shares	30/09
Enanta Pharmaceuticals announces $50 million public offering of common stock	30/09
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock	30/09
Enanta Pharmaceuticals Says Zelicapavir Misses Phase 2 Primary Endpoint, But Shows RSV Improvement	29/09
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults	29/09
Enanta's RSV treatment helps speed up recovery in study, shares surge	29/09
Enanta Pharmaceuticals reports positive Phase 2b results for RSV drug zelicapavir	29/09
Enanta Pharmaceuticals Reports Positive Topline Results from Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus in High-Risk Adults	29/09
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults	26/09
Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Financial and Administrative Officer	03/09
Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Administrative Officer	03/09
Enanta Pharmaceuticals Chief Financial, Administrative Officer Dies	03/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Enanta Pharmaceuticals, Inc.

Aandelen

ENTA

US29251M1062

Farmaceutische producten

Andere talen

Filters